Establishment of patient reporting scheme in the UK and its implications

doi:10.19803/j.1672-8629.20230476

Abstract

Abstract: Objective To analyze the process in which the UK established the patient reporting scheme and provide reference for the start of an adverse drug reaction patient reporting scheme in China. Methods Based on literature review, the process of establishing the patient reporting scheme in the UK was analyzed. Results UK launched a nationwide pilot program to collect patients’ reports directly from patients, which greatly increased the total number of ADR reports. Subsequently, the patient reporting scheme was officially implemented. Conclusion The patient reporting scheme in the UK is a supplement to the existing yellow card scheme. Only through direct patient reporting can we get the expected results of the patient reporting scheme. It is recommended that China learn from the related experience in the UK to initiate a pilot program to start a patient reporting scheme that is workable in China.

Key words: pharmacovigilance, yellow card scheme, adverse drug reaction, patient reporting, scheme, UK

CLC Number:

R951
R994.11

PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.

References

[1] World Health Organization.Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action[R]. World Health Organization, 2002.
[2] VAN HUNSEL F, HÄRMARK L, PAL S, et al. Experiences with adverse drug reaction reporting by patients: an 11-country survey[J]. Drug Saf, 2012, 35: 45-60.
[3] MARGRAFF F, BERTRAM D.Adverse drug reaction reporting by patients: an overview of fifty countries[J]. Drug Saf, 2014, 37: 409-419.
[4] World Health Organization.Safety monitoring of medical products: reporting system for the general public[R/OL]. [2023-04-07].https://www.who.int/.
[5] PARRETTA E, RAFANIELLO C, MAGRO L, et al.Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy[J]. Expert Opin Drug Saf, 2014, 13(Suppl 1): S21-S29.
[6] BORG JJ, AISLAITNER G, PIROZYNSKI M, et al.Strengthening and rationalizing pharmacovigilance in the EU: where is Europe
heading to? a review of the new EU legislation on pharmacovigilance[J].Drug Saf, 2011, 34: 187-197.
[7] VARGESSON N.The teratogenic effects of thalidomide on limbs[J]. Journal of Hand Surgery, 2019, 44(1): 88-95.
[8] CHAPLIN S.Monitoring drug safety: is the yellow card scheme struggling[J]. Prescriber, 2019, 30(9): 32-34.
[9] GILES S.Yellow card scheme reaches 50[J]. Prescriber, 2015, 26(18): 6.
[10] NONE. Nurses join yellow card scheme as it goes online[J]. React Wkly, 2002, 927(1): 3.
[11] LAWSON DH.The yellow card: mark II[J]. Br J clin Pharmac, 1991, 301: 1234.
[12] NONE. Yellow card system given the red card[J]. React Wkly, 1992, 395(4):10
[13] BELTON KJ, LEWIS SC, PAYNE S, et al.Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom[J]. Br J clin Pharmac, 1995, 39(3): 223-226.
[14] SWEIS D, WONG D.A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain[J]. Drug Saf, 2000, 23(2): 165-172.
[15] HAWCUTT DB, MAINIE P, RIORDAN A, et al.Reported paediatric adverse drug reactions in the UK 2000-2009[J]. Br J clin Pharmac, 2012, 73(3): 437-446.
[16] NONE. UK‘yellow card’ADR reporting updated[J]. React Wkly, 2000, 820(1): 2.
[17] BLENKINSOPP A, WILKIE P, WANG M, et al.Patient reporting of suspected adverse drug reactions: a review of published literature and international experience[J]. Br J clin Pharmac, 2006, 63(2): 148-156.
[18] NONE. Following an independent review of the UK Yellow Card Scheme, the MHRA is to pilot patient reporting[J]. React Wkly, 2004, 1001(1): 21.
[19] AVERY AJ, ANDERSON C, BOND CM, et al.Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys[J]. Health Technology Assessment, 2011, 15(20): 129.
[20] NONE. The yellow card scheme for reporting adverse drug reactions (ADRs) by patients in the UK will complement, not replace, the yellow card reports[J]. React Wkly, 2006, 1109(1): 3.
[21] WEBB DJ.An agenda for UK clinical pharmacology: UK medicines policy: the role of clinical pharmacologists[J]. Br J Clin Pharmac, 2012, 73(6): 948-952.
[22] Medicines & Healthcare Products Regulatory Agency. Contact us[EB/OL].(2023-08-04)[2023-08-04].https://yellowcard.mhra.gov.uk/contact-us/.
[23] WARK S.The Yellow Card Scheme - new reporters including patients, 32nd UK Medicines Information Conference Proceedings[C]. Chester: UK Medicines Information, 2006.
[24] NONE. UK yellow card scheme: pharmacists to encourage patient reporting[J]. Pharm Med, 2008, 22(2): 129.
[25] INÁCIO P, CAVACO A, ALLAN E, et al. Key pharmacovigilance stakeholders’experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union[J]. Public Health, 2018, 155: 119-128.
[26] The Lancet.Improving ADR Reporting[J]. The Lancet, 2002, 360(9344): 1435.
[27] KRSKA J, ANDERSON C, MURPHY E, et al.How patient reporters identify adverse drug reactions[J]. Drug Safety, 2011, 34(5): 429-436.
[28] Medicines and Healthcare Products Regulatory Agency. Yellow Card Scheme first anniversary for patient reporting - reports from the public up 50%[J]. React Wkly, 2009, 1241(1): 3.
[29] WISE J.GPs are urged to report adverse drug reactions after a 37% slump over nine years[J]. BMJ, 2013, 34(feboll): f690.
[30] Gov.UK. MHRA Yellow Card Scheme looks to the future at 50th anniversary forum [EB/OL].(2014-11-25)[2023-08-04].https://www.gov.uk/government/news/yellow-card-scheme-looks-to-the-future-at-50th-anniversary-forum.
[31] NONE. MHRA reports a milestone: 1 million yellow card reports[J]. React Wkly, 2020, 1830(1): 5.
[32] WANG D, REN JT, DONG D, et al.Trend analysis of ten-year annual reports on adverse drug reaction monitoring[J]. Chinese Journal of Pharmocovigilance(中国药物警戒), 2020, 17(5): 276-283.
[33] NMPA. NMPA announcement on direct reporting of adverse reactions by drug marketing authorization holders (No. 66, 2018) [EB/OL]. (2018-09-30)[2023-08-01]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180930174301286.html.
[34] NMPA. Annual report for national adverse drug reaction monitoring (2020) [EB/OL].(2021-03-26) [2023-08-01]. https://www.cdr-adr.org.cn/center_news/202103/t20210326_48413.html.
[35] NMPA. Annual report for national adverse drug reaction monitoring (2021) [EB/OL].(2022-03-30) [2023- 08-01]. https://www.cdr-adr.org.cn/tzgg_home/202203/t20220330_49585.html.
[36] MOH. Regulations for the administration of adverse drug reaction reporting and monitoring (No.81, 2011)[ EB/OL]. (2011-05-04)[2023-08-21]. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20110504162501325.html.
[37] WANG CG, WANG DF, XU LL, et al.Investigation and reflection on the demand of public reporting of adverse drug reaction in China[J]. Chinese Journal of Pharmocovigilance(中国药物警戒), 2017, 14(7): 402-406.